XLO

Xilio Therapeutics, Inc. Common Stock

0.70

USD

XLO Earnings Reports

Positive Surprise Ratio

XLO beat 10 of 17 last estimates.

59%

Next Report

Date of Next Report

Mar 09, 2026

Estimate for Q4 25 (Revenue/ EPS)

$8.04M

-$0.12

Implied change from Q3 25 (Revenue/ EPS)

-57.83%

Implied change from Q4 24 (Revenue/ EPS)

+366.33%

-40.00%

Xilio Therapeutics, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, XLO reported earnings of 0.00 USD per share (EPS) for Q3 25, beating the estimate of -0.03 USD, resulting in a 80.20% surprise. Revenue reached 19.07 million, compared to an expected 18.82 million, with a 1.30% difference. The market reacted with a -9.28% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 2 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 8.04 million USD, implying an -- of --% EPS, and decrease of -57.83% in Revenue from the last quarter.

FAQ

What were Xilio Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Xilio Therapeutics, Inc. Common Stock reported EPS of $0.00, beating estimates by 80.2%, and revenue of $19.07M, 1.3% above expectations.

How did the market react to Xilio Therapeutics, Inc. Common Stock's Q3 2025 earnings?

The stock price moved down -9.28%, changed from $0.77 before the earnings release to $0.70 the day after.

When is Xilio Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 09, 2026.

What are the forecasts for Xilio Therapeutics, Inc. Common Stock's next earnings report?

Based on 2 analysts, Xilio Therapeutics, Inc. Common Stock is expected to report EPS of -$0.12 and revenue of $8.04M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.